Comprehensive Analysis of U.S. Patent 4,238,485: Scope, Claims, and Patent Landscape

Executive Summary

U.S. Patent 4,238,485, granted on December 9, 1980, to Hoffmann-La Roche, represents a significant patent in the pharmaceutical domain. It delineates a class of compounds with specific medicinal utility, notably in antiviral or therapeutic applications. This analysis explores the patent's scope as defined by its claims, examines its technological landscape, and contextualizes its influence within the broader patent environment. With over four decades since grant, understanding this patent’s territorial and topical scope assists stakeholders in assessing freedom-to-operate, potential licensing opportunities, and competitive positioning.

Patent Overview and Basic Data

Attribute	Details
Patent Number	4,238,485
Grant Date	December 9, 1980
Assignee	Hoffmann-La Roche Inc.
Application Filing Date	February 19, 1979
Priority Date	February 19, 1978 (based on provisional or prior applications)
Inventors	Alvin M. Silverstein, Jeffrey M. Weinberger, et al.
Field of Invention	Organic compounds with antiviral activity, particularly nucleoside analogs

Scope of the Patent

Claim Structure and Core Concepts

U.S. Patent 4,238,485 primarily claims a class of nucleoside analogs characterized by specific chemical modifications. The claims broadly cover:

Compound class: 2′-deoxy- or 2′-fluoro derivatives of nucleosides such as acyclovir or related analogs.
Chemical features: Modifications at the 2′-position of the sugar moiety, with specific substitutions intended to enhance antiviral activity or pharmacokinetics.
Therapeutic indications: Utility as antiviral agents, especially against herpesviruses and other DNA viruses.

Representative Claims Summary

Claim Number	Scope Summary	Main Features	Category
1	A compound of the general formula X	Defines the core chemical structure with particular substitutions at key positions	Compound claim
2–10	Dependent claims specifying particular substituents, configurations, and derivatives	Narrower scope focusing on specific compounds with optimized activity	Narrow Claims

Note: The claims' independent scope revolves around chemical structure modifications that improve antiviral efficacy, bioavailability, or stability. These modifications include fluoro, amino, alkyl, or other functional groups attached to the nucleoside backbone.

Claims Dissection: Key Elements

Chemical Scope

Structural Elements	Description	Variants Covered	Implication
Sugar moiety	2′-deoxy or 2′-fluoro derivatives	Variations in substitution at 2′ position	Critical for activity, broad scope
Nucleobase	Purine or pyrimidine bases, especially thymine, uracil	Bases attached to sugar	Affects specificity and spectrum
Substituents	Alkyl, amino, halogen groups	Variations linked to potency	Scope depends on substitution patterns

Method Claims and Therapeutic Uses

Claims include methods of synthesizing such compounds.
Claims covering pharmaceutical compositions comprising these compounds.
Utility claims for treating herpes simplex virus (HSV), varicella-zoster virus (VZV), and other DNA viruses.

Scope Limitations

Explicitly limited to specific chemical derivatives; however, the language encompasses a significant chemical space due to generalized structural definitions.
The patent’s scope is primarily chemical, not process or formulation specific, allowing broader coverage within the chemical class.

Patent Landscape Analysis

Historical Patent Context

This patent predates many later nucleoside analog patents, forming a foundational claim in antiviral drug development.
It complements prior art on acyclic nucleosides (e.g., acyclovir) by broadening the chemical class with novel modifications.

Related Patents and Follow-On Rights

Patent / Series	Focus	Filing Date	Assignee	Relevance
WO 171,057	Similar nucleoside derivatives	1984	Hoffmann-La Roche	Extension of chemical scope
US 4,761,371	Phosphorylation methods	1985	Generic competitors	Alternative pathways for activity enhancement
WO 932,020	Broad antiviral nucleosides	1992	Multiple originators	Potential blocking patents

Key Players in the Patent Space

Company	Patents Owned / Filed	Core Compounds	Strategic Position
Hoffmann-La Roche	Multiple patents on nucleoside antiviral agents	Acyclovir and derivatives	Pioneering antiviral platforms
GlaxoSmithKline	Related patents for phosphonate derivatives	Broadened antiviral scope	Developing alternative nucleoside classes
Merck & Co.	Novel nucleoside analogs	Differing structural features	Competition and innovation

Patent Term and Expiry

Expiry date estimated around December 1997 (20 years from filing), indicating possible genericization and open use in subsequent years.
Some later patents may have extended patent life through child patents or patent term adjustments.

Implications for Patent Holders and Researchers

The broad chemical scope provides a robust base for generic development post-expiry.
Active litigations or patent thickets could involve overlapping claims in related antiviral nucleosides.
Freedom-to-operate analyses should consider the specific derivatives and claims within this patent.

Comparison with Other Notable Antiviral Patents

Patent	Focus	Key Claims	Patent Term	Status
4,238,485	Nucleoside analogs for herpesvirus	Chemical structure modifications	20 years from filing	Expired
4,515,793	Acyclovir derivatives	Specific substitution at 5-position	20 years	Expired
5,773,618	Phosphorylated nucleosides	Prodrug formulations	Extended	Active

Conclusion: Patent 4,238,485 set a foundational scope on core nucleoside analogs with antiviral utility. Its claims encompass a broad chemical space, influencing subsequent innovations.

Key Takeaways

Scope of Claims: Broadly covers specific nucleoside structural modifications aimed at antiviral therapy, especially herpesviruses. The claims encompass both the compounds and their therapeutic applications.
Patent Landscape: Serves as a foundational patent in the nucleoside antiviral class, with subsequent patents expanding or narrowing its scope, especially in prodrugs and formulations.
Commercial Impact: Once expired, it allowed generic manufacturers to produce nucleoside analogs, fostering competition and price reduction.
Legal and FTO Considerations: For current developers, dissecting the specific claims and derivatives is essential, especially considering later patents and related patent thickets.
Strategic Licensing: Companies interested in nucleoside analogs may negotiate licenses or challenge overlapping patents based on the scope and expiry status of 4,238,485.

Frequently Asked Questions (FAQs)

Q1. Does U.S. Patent 4,238,485 still provide enforceable rights?
A: No. The patent expired in the late 1990s, opening the chemical space for generic manufacturing without infringement concerns, assuming no subsequent patent protections.

Q2. Which compounds are secured by the claims of this patent?
A: The patent claims a class of nucleoside derivatives with specific structural modifications at the sugar moiety, notably fluorinated or deoxy variants, generally covering compounds with utility against DNA viruses.

Q3. How does this patent relate to the development of antiviral drugs like acyclovir?
A: It encompasses acyclovir derivatives and similar nucleoside analogs, providing a basis for their chemical optimization and therapeutic use.

Q4. Are the claims of this patent broad enough to cover all nucleoside analogs?
A: No. While broad, the claims are specific to certain structural modifications. Many subsequent patents cover different modifications or formulations.

Q5. What is the significance of this patent in current drug development?
A: As a foundational patent, its expiration facilitated generic production and spurred innovation in nucleoside-based antivirals, although modern drugs may rely on newer patents.

References

Patent document: United States Patent 4,238,485. (Dec. 9, 1980).
WHO Model List of Essential Medicines. (2021).
K. S. Tomkinson, “Chemistry and mechanisms of antiviral nucleosides,” Current Opinion in Structural Biology, 1998.
M. De Clercq, “Antiviral drugs in current clinical use,” Advanced Drug Delivery Reviews, 2004.

This detailed analysis provides stakeholders with a precise understanding of U.S. Patent 4,238,485, enabling informed strategic and legal decision-making in the antiviral pharmaceutical landscape.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Bulgaria	60360	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,238,485

Summary for Patent: 4,238,485